Compare POWI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWI | ACAD |
|---|---|---|
| Founded | 1988 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.8B |
| IPO Year | 1997 | 2000 |
| Metric | POWI | ACAD |
|---|---|---|
| Price | $86.86 | $21.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 22 |
| Target Price | ★ $60.00 | $30.55 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 0.06 | 0.02 |
| Revenue | $443,504,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $8.12 | $18.80 |
| Revenue Next Year | $16.54 | $11.70 |
| P/E Ratio | $1,399.17 | ★ $1,058.75 |
| Revenue Growth | 5.86 | ★ 40.45 |
| 52 Week Low | $30.86 | $19.69 |
| 52 Week High | $84.90 | $28.35 |
| Indicator | POWI | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 73.54 | 45.81 |
| Support Level | $44.24 | $20.11 |
| Resistance Level | N/A | $22.03 |
| Average True Range (ATR) | 5.03 | 0.70 |
| MACD | 0.57 | -0.05 |
| Stochastic Oscillator | 91.77 | 35.70 |
Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.